CHART, page-27

it will increase the valuation of NYR considerably and big pharma especially Boehringer would be the first ones targeting NYR. But don’t think management should take any offer as the upcoming cardiovascular indication improved significantly in their outcome for the patient. Go the whole way allowing shareholders to ride this as long as possible. License deal is better on every indication adding huge value along the way